Determination of lipid requirements in black soldier fly through semi-purified diets.

The insect market is still far from an effective upscale and, to achieve this goal, it is necessary to know the BSF dietary requirements for the production maximization. Worldwide, given the waste variability, is not always easy to identify the optimal waste-based mixture that can allow to reach the best production, in terms of quantity and quality. Due this reason, nutritional need ranges are the basic knowledge, affordable for everyone, to increase the profitability of the insect farming. The study aims to evaluate the effects of 6 semi-purified, isonitrogenous and isoenergetic diets (SPII) with increasing lipid levels (1%, L1; 1.5%, L1.5; 2.5%, L2.5; 3.5% L3.5; 4.5%, L4.5) on BSF life history traits (6 replicates/treatment and 100 larvae/replicate). The Gainesville diet was used as environmental control. Considering the whole larval stage, 4.5% lipid level guarantees better performance when compared to content lower than 2.5%. The L4.5 10-day-old larvae yielded greater when compared to the other dietary treatments. At 14 and 18 days of age, the larvae of the groups above 2.5% performed better than L1, while the L1.5 showed intermediate results. Lipid levels below 1.5% on DM, when compared to 4.5%, resulted in a smaller prepupa and pupa size. The results obtained on the adult stage do not allow the identification of a lipid levels ideal range, as in the larval stage. In conclusion, in the whole larval stage and in prepupae/pupae phases, lipid percentage lower than (or equal to) 1% have a negative effect on growth. Other research will be needed in order to evaluate lipid levels above 4.5% on DM.

Reporter gene technology to assess activity of antimycobacterial agents in macrophages.

Reporter strains of Mycobacterium tuberculosis and Mycobacterium bovis BCG endogenously expressing firefly luciferase were used in bioluminescence assays to evaluate the activities of isoniazid and rifampin against mycobacteria sequestered in human macrophages. This methodology allowed the efficacy of antibiotics against intracellular mycobacteria to be assessed without the labor-intensive procedures and protracted incubation requirements associated with conventional CFU determinations.

Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery.

Bioluminescence-based assays to indicate antimicrobial susceptibility have been developed and validated for recombinant strains of Mycobacterium tuberculosis, Mycobacterium bovis BCG, Mycobacterium avium, and Mycobacterium intracellulare expressing an integrated eukaryotic luciferase gene. MICs determined with these bioluminescence assays for several antimycobacterial agents, including isoniazid, ethambutol, rifampin, amikacin, streptomycin, ciprofloxacin, and clarithromycin, compared favorably with traditional BACTEC methods and visual estimations of the inhibitory end point. Assay methodology has been optimized for the analysis of large numbers of novel compounds and is simple, inexpensive, and labor efficient. The availability of these four recombinant mycobacteria has permitted a strategy for drug discovery employing the nonpathogenic BCG strain for mass screening purposes with subsequent confirmation of activity against the pathogenic mycobacteria. Furthermore, evidence suggests that the BCG-based screen may allow the direct identification of bactericidal agents.

Differential susceptibilities of enterococcal species to elfamycin antibiotics.

The elfamycins are a class of naturally occurring antibiotics not currently used in the therapy of human disease. Enterococcus faecium and closely related species (Enterococcus durans and Enterococcus hirae) are susceptible to these antibiotics, while isolates of Enterococcus faecalis and other enterococcal species are highly resistant. Among enterococci, susceptibility or resistance to elfamycins appears to be determined by the bacterial protein synthesis elongation factor EF-Tu. Elfamycin susceptibility may be a useful adjunct for rapidly distinguishing E. faecalis and E. faecium in the clinical microbiology laboratory and/or as a supplementary test for use in determining the species of enterococci.

In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).

MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.